Rondecabtagene autoleucel

Rondecabtagene autoleucel (LYL314) is a CAR-T cell therapy developed by Lyell Immunopharma. Its targets are CD19 and CD20 (the sponsor names CD19/CD20). The sponsor states: An autologous, dual-targeting CD19/CD20 CAR T-cell product using an OR-gated CAR construct that fully activates on recognition of either antigen, enriched for CD62L-positive naive/central memory T cells for enhanced proliferation and persistence. ClinicalTrials.gov describes the intervention as: An autologous, dual-targeting CD19/20 CAR T-cell candidate. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07188558 (A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy), in diffuse large B-cell lymphoma and hodgkin lymphoma. The largest, NCT07188558, plans to enrol 400 participants with primary completion expected 2029-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.